Please enable JavaScript to continue using this application.

Compare $CAI vs $PTGX | Chartloom

Compare

$CAI vs $PTGX

Caris Life Sciences Inc · Protagonist Therapeutics Inc

CAI

Caris Life Sciences Inc

PTGX

Protagonist Therapeutics Inc

Compare $CAI vs $PTGX

Comparing Caris Life Sciences Inc and Protagonist Therapeutics Inc

CAICaris Life Sciences Inc

PTGXProtagonist Therapeutics Inc

CAICaris Life Sciences Inc

Market cap

$8.40B

P/E (TTM)

79.91x

Forward P/E (NTM)

101.64x

Forward P/S (NTM)

7.48x

Rev growth (TTM)

24.4%

YTD performance

10.1%

52W performance

-9.9%

FCF yield

1.5%

PTGXProtagonist Therapeutics Inc

Market cap

$9.24B

P/E (TTM)

123.10x

Forward P/E (NTM)

77.71x

Forward P/S (NTM)

23.74x

Rev growth (TTM)

34.8%

YTD performance

64.9%

52W performance

120.1%

FCF yield

1.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CAI

PTGX

Detailed metrics comparison

CAI

Caris Life Sciences Inc

PTGX

Protagonist Therapeutics Inc

Market Cap

CAI$8.40B

PTGX$9.24B

Enterprise Value

CAI$8.10B

PTGX$8.82B

Price

CAI$29.70

PTGX$143.73

P/E Ratio

CAI79.91x

PTGX123.10x

P/S Ratio

CAI8.48x

PTGX32.78x

EV/Sales

CAI8.18x

PTGX31.29x

EV/EBITDA

CAI45.95x

PTGX140.17x

P/B Ratio

CAI13.52x

PTGX10.77x

P/FCF Ratio

CAI67.73x

PTGX70.79x

EV/FCF

CAI65.33x

PTGX67.57x

PEG Ratio

CAIN/A

PTGX2.95x

Forward P/E (NTM)

CAI101.64x

PTGX77.71x

Forward P/S (NTM)

CAI7.48x

PTGX23.74x

Revenue (TTM)

CAI$990M

PTGX$282M

Revenue Growth (YoY)

CAI24.4%

PTGX34.8%

Forward Rev Growth

CAI18.2%

PTGX-70.6%

Gross Margin (TTM)

CAI69.7%

PTGX0.0%

Operating Margin (TTM)

CAI12.7%

PTGX20.7%

EBITDA Margin (TTM)

CAI17.6%

PTGX21.2%

Net Margin (TTM)

CAI10.6%

PTGX29.4%

FCF Margin (TTM)

CAI12.5%

PTGX46.3%

Net Income (TTM)

CAI$105M

PTGX$83M

FCF (TTM)

CAI$124M

PTGX$131M

EPS (TTM)

CAI$0.37

PTGX$1.17

ROE (TTM)

CAI18.8%

PTGX12.0%

ROA (TTM)

CAI9.3%

PTGX11.2%

ROIC (TTM)

CAI11.2%

PTGX12.0%

Cash

CAI$691M

PTGX$420M

Debt

CAI$393M

PTGX$0

Net Cash/Debt

CAI$298M

PTGX$420M

Current Ratio (TTM)

CAI5.53x

PTGX21.71x

Quick Ratio (TTM)

CAI4.78x

PTGX21.58x

Debt/Equity (TTM)

CAI0.66x

PTGX0.00x

Debt/Assets (TTM)

CAI0.0%

PTGX0.0%

Interest Coverage (TTM)

CAIN/A

PTGXN/A

Net Debt/EBITDA (TTM)

CAI0.00x

PTGX0.00x

Beta

CAI0.40

PTGX1.19

52W Performance

CAI-9.9%

PTGX120.1%

YTD Performance

CAI10.1%

PTGX64.9%

% from 52W High

CAI-11.7%

PTGX-10.6%

% from 52W Low

CAI109.3%

PTGX119.2%

Asset Turnover (TTM)

CAI0.88x

PTGX0.38x

FCF Yield (TTM)

CAI1.5%

PTGX1.4%

Earnings Yield (TTM)

CAI1.3%

PTGX0.9%

Dividend Yield (TTM)

CAIN/A

PTGXN/A

Rule of 40

CAI37.0

PTGX81.1

EV/GP/RG

CAI0.86

PTGXN/A

Ticker research

View CAI research View PTGX research

Metric	CAI Caris Life Sciences Inc	PTGX Protagonist Therapeutics Inc
Market & Valuation
Market Cap	$8.40B	$9.24B
Enterprise Value	$8.10B	$8.82B
Price	$29.70	$143.73
P/E Ratio	79.91x	123.10x
P/S Ratio	8.48x	32.78x
EV/Sales	8.18x	31.29x
EV/EBITDA	45.95x	140.17x
P/B Ratio	13.52x	10.77x
P/FCF Ratio	67.73x	70.79x
EV/FCF	65.33x	67.57x
PEG Ratio	N/A	2.95x
Forward P/E (NTM)	101.64x	77.71x
Forward P/S (NTM)	7.48x	23.74x
Revenue & Growth
Revenue (TTM)	$990M	$282M
Revenue Growth (YoY)	24.4%	34.8%
Forward Rev Growth	18.2%	-70.6%
Profitability
Gross Margin (TTM)	69.7%	0.0%
Operating Margin (TTM)	12.7%	20.7%
EBITDA Margin (TTM)	17.6%	21.2%
Net Margin (TTM)	10.6%	29.4%
FCF Margin (TTM)	12.5%	46.3%
Net Income (TTM)	$105M	$83M
FCF (TTM)	$124M	$131M
EPS (TTM)	$0.37	$1.17
ROE (TTM)	18.8%	12.0%
ROA (TTM)	9.3%	11.2%
ROIC (TTM)	11.2%	12.0%
Financial Health
Cash	$691M	$420M
Debt	$393M	$0
Net Cash/Debt	$298M	$420M
Current Ratio (TTM)	5.53x	21.71x
Quick Ratio (TTM)	4.78x	21.58x
Debt/Equity (TTM)	0.66x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.40	1.19
52W Performance	-9.9%	120.1%
YTD Performance	10.1%	64.9%
% from 52W High	-11.7%	-10.6%
% from 52W Low	109.3%	119.2%
Efficiency & Yields
Asset Turnover (TTM)	0.88x	0.38x
FCF Yield (TTM)	1.5%	1.4%
Earnings Yield (TTM)	1.3%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	37.0	81.1
EV/GP/RG	0.86	N/A
Ticker research	View CAI research	View PTGX research

Valuation

P/E Ratio

CAI

79.91x

PTGX

123.10x

P/S Ratio

CAI

8.48x

PTGX

32.78x

EV/FCF

CAI

65.33x

PTGX

67.57x

Growth & revenue

Revenue Growth TTM

PTGX

34.8%

CAI

24.4%

Forward Revenue Growth

CAI

18.2%

PTGX

-70.6%

Profitability & performance

Gross Margin

CAI

69.7%

PTGX

0.0%

ROE

CAI

18.8%

PTGX

12.0%

FCF Yield %

CAI

1.5%

PTGX

1.4%

52-Week Performance

PTGX

120.1%

CAI

-9.9%

Detailed metrics comparison

CAI

Caris Life Sciences Inc

PTGX

Protagonist Therapeutics Inc

Market Cap

CAI$8.40B

PTGX$9.24B

Enterprise Value

CAI$8.10B

PTGX$8.82B

Price

CAI$29.70

PTGX$143.73

P/E Ratio

CAI79.91x

PTGX123.10x

P/S Ratio

CAI8.48x

PTGX32.78x

EV/Sales

CAI8.18x

PTGX31.29x

EV/EBITDA

CAI45.95x

PTGX140.17x

P/B Ratio

CAI13.52x

PTGX10.77x

P/FCF Ratio

CAI67.73x

PTGX70.79x

EV/FCF

CAI65.33x

PTGX67.57x

PEG Ratio

CAIN/A

PTGX2.95x

Forward P/E (NTM)

CAI101.64x

PTGX77.71x

Forward P/S (NTM)

CAI7.48x

PTGX23.74x

Revenue (TTM)

CAI$990M

PTGX$282M

Revenue Growth (YoY)

CAI24.4%

PTGX34.8%

Forward Rev Growth

CAI18.2%

PTGX-70.6%

Gross Margin (TTM)

CAI69.7%

PTGX0.0%

Operating Margin (TTM)

CAI12.7%

PTGX20.7%

EBITDA Margin (TTM)

CAI17.6%

PTGX21.2%

Net Margin (TTM)

CAI10.6%

PTGX29.4%

FCF Margin (TTM)

CAI12.5%

PTGX46.3%

Net Income (TTM)

CAI$105M

PTGX$83M

FCF (TTM)

CAI$124M

PTGX$131M

EPS (TTM)

CAI$0.37

PTGX$1.17

ROE (TTM)

CAI18.8%

PTGX12.0%

ROA (TTM)

CAI9.3%

PTGX11.2%

ROIC (TTM)

CAI11.2%

PTGX12.0%

Cash

CAI$691M

PTGX$420M

Debt

CAI$393M

PTGX$0

Net Cash/Debt

CAI$298M

PTGX$420M

Current Ratio (TTM)

CAI5.53x

PTGX21.71x

Quick Ratio (TTM)

CAI4.78x

PTGX21.58x

Debt/Equity (TTM)

CAI0.66x

PTGX0.00x

Debt/Assets (TTM)

CAI0.0%

PTGX0.0%

Interest Coverage (TTM)

CAIN/A

PTGXN/A

Net Debt/EBITDA (TTM)

CAI0.00x

PTGX0.00x

Beta

CAI0.40

PTGX1.19

52W Performance

CAI-9.9%

PTGX120.1%

YTD Performance

CAI10.1%

PTGX64.9%

% from 52W High

CAI-11.7%

PTGX-10.6%

% from 52W Low

CAI109.3%

PTGX119.2%

Asset Turnover (TTM)

CAI0.88x

PTGX0.38x

FCF Yield (TTM)

CAI1.5%

PTGX1.4%

Earnings Yield (TTM)

CAI1.3%

PTGX0.9%

Dividend Yield (TTM)

CAIN/A

PTGXN/A

Rule of 40

CAI37.0

PTGX81.1

EV/GP/RG

CAI0.86

PTGXN/A

Ticker research

View CAI research View PTGX research

Metric	CAI Caris Life Sciences Inc	PTGX Protagonist Therapeutics Inc
Market & Valuation
Market Cap	$8.40B	$9.24B
Enterprise Value	$8.10B	$8.82B
Price	$29.70	$143.73
P/E Ratio	79.91x	123.10x
P/S Ratio	8.48x	32.78x
EV/Sales	8.18x	31.29x
EV/EBITDA	45.95x	140.17x
P/B Ratio	13.52x	10.77x
P/FCF Ratio	67.73x	70.79x
EV/FCF	65.33x	67.57x
PEG Ratio	N/A	2.95x
Forward P/E (NTM)	101.64x	77.71x
Forward P/S (NTM)	7.48x	23.74x
Revenue & Growth
Revenue (TTM)	$990M	$282M
Revenue Growth (YoY)	24.4%	34.8%
Forward Rev Growth	18.2%	-70.6%
Profitability
Gross Margin (TTM)	69.7%	0.0%
Operating Margin (TTM)	12.7%	20.7%
EBITDA Margin (TTM)	17.6%	21.2%
Net Margin (TTM)	10.6%	29.4%
FCF Margin (TTM)	12.5%	46.3%
Net Income (TTM)	$105M	$83M
FCF (TTM)	$124M	$131M
EPS (TTM)	$0.37	$1.17
ROE (TTM)	18.8%	12.0%
ROA (TTM)	9.3%	11.2%
ROIC (TTM)	11.2%	12.0%
Financial Health
Cash	$691M	$420M
Debt	$393M	$0
Net Cash/Debt	$298M	$420M
Current Ratio (TTM)	5.53x	21.71x
Quick Ratio (TTM)	4.78x	21.58x
Debt/Equity (TTM)	0.66x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.40	1.19
52W Performance	-9.9%	120.1%
YTD Performance	10.1%	64.9%
% from 52W High	-11.7%	-10.6%
% from 52W Low	109.3%	119.2%
Efficiency & Yields
Asset Turnover (TTM)	0.88x	0.38x
FCF Yield (TTM)	1.5%	1.4%
Earnings Yield (TTM)	1.3%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	37.0	81.1
EV/GP/RG	0.86	N/A
Ticker research	View CAI research	View PTGX research